Jessica Allen

Oral agents have changed the CLL treatment landscape. But how does their cost affect patients? Here's a review of our #ASH24 abstract on the relationship between financial toxicity, medication adherence, and health-related QOL in CLL pts on 1L oral therapy #lymsm 🧵/1

🚨Just out @CCR_AACR 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks @dgermain21 & collabs! aacrjournals.org/clincancerres/…

Dr. @majorajay @CUHematology contributed (with @JessicaAllenMD) to a large multicenter study of real-world outcomes of polatuzumab in frontline and relapsed/refractory DLBCL, now published @CCR_AACR. #lymsm aacrjournals.org/clincancerres/…

Our very own @majorajay was interviewed by @RahulBanerjeeMD for The HemOnc Pulse podcast at @Blood_Cancers about patient-reported outcomes and his latest manuscript on adverse event measurement @TheLancetHaem. #lymsm cc @CUAnschutz @CUCancerCenter bloodcancerstoday.com/podcast/toxici…

Correction to post 5, meant to include this table!

47 patients completed PRO instruments at baseline. Longitudinal completion rates remained high (85% 3 mo, 83% 6mo). - Median age 66, 53% male, 89% white - 47% medicare, 45% private insurance - 53% concurrent obinutuzumab - 66% had $0 copay, 57% grant or PAP support #ASH24 /5

Oral agents have changed the CLL treatment landscape. But how does their cost affect patients? Here's a review of our #ASH24 abstract on the relationship between financial toxicity, medication adherence, and health-related QOL in CLL pts on 1L oral therapy #lymsm 🧵/1

Lastly, the biggest thanks go to my mentor @majorajay , whose passion for PROs and quality of life investigation is incredibly inspiring. Thank you as well to everyone involved @UChicago and @ACCORDSResearch ! /end bit.ly/3P4R0sy

Thank you for tuning in! This is a mid-study analysis, and we aim to enroll 75 patients before final analysis. We welcome any feedback and impressions from this study as enrollment continues! /14 bit.ly/3P4R0sy

Sneak peek of my mentee @vpizzuti44's heatmap analysis of longitudinal PROs from our @CUHematology BISON-PRO Quality of Life Study (bison-pro.org). His abstract is at tonight's #ASH24 poster session; big congrats on an ASH Achievement Award for his work! #MajorPROsASH